DK3337829T3 - FREMGANGSMÅDE OG SAMMENSÆTNING TIL BEHANDLING AF CANCER, DRAB AF METASTATISKE CANCERCELLER OG FOREBYGGELSE AF CANCERMETASTASE VED HJÆLP AF ANTISTOFFER MOD AVANCEREDE GLYKERINGSSLUTPRODUKTER (age) - Google Patents

FREMGANGSMÅDE OG SAMMENSÆTNING TIL BEHANDLING AF CANCER, DRAB AF METASTATISKE CANCERCELLER OG FOREBYGGELSE AF CANCERMETASTASE VED HJÆLP AF ANTISTOFFER MOD AVANCEREDE GLYKERINGSSLUTPRODUKTER (age) Download PDF

Info

Publication number
DK3337829T3
DK3337829T3 DK17708098.3T DK17708098T DK3337829T3 DK 3337829 T3 DK3337829 T3 DK 3337829T3 DK 17708098 T DK17708098 T DK 17708098T DK 3337829 T3 DK3337829 T3 DK 3337829T3
Authority
DK
Denmark
Prior art keywords
cancer
glycing
metastase
killing
age
Prior art date
Application number
DK17708098.3T
Other languages
English (en)
Inventor
Lewis S Gruber
Original Assignee
Siwa Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siwa Corp filed Critical Siwa Corp
Application granted granted Critical
Publication of DK3337829T3 publication Critical patent/DK3337829T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17708098.3T 2016-02-19 2017-02-16 FREMGANGSMÅDE OG SAMMENSÆTNING TIL BEHANDLING AF CANCER, DRAB AF METASTATISKE CANCERCELLER OG FOREBYGGELSE AF CANCERMETASTASE VED HJÆLP AF ANTISTOFFER MOD AVANCEREDE GLYKERINGSSLUTPRODUKTER (age) DK3337829T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662297744P 2016-02-19 2016-02-19
US201662425495P 2016-11-22 2016-11-22
PCT/US2017/018185 WO2017143073A1 (en) 2016-02-19 2017-02-16 Method and composition for treating cancer, killing metastatic cancer cells and preventing cancer metastasis using antibody to advanced glycation end products (age)

Publications (1)

Publication Number Publication Date
DK3337829T3 true DK3337829T3 (da) 2020-02-17

Family

ID=58191665

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17708098.3T DK3337829T3 (da) 2016-02-19 2017-02-16 FREMGANGSMÅDE OG SAMMENSÆTNING TIL BEHANDLING AF CANCER, DRAB AF METASTATISKE CANCERCELLER OG FOREBYGGELSE AF CANCERMETASTASE VED HJÆLP AF ANTISTOFFER MOD AVANCEREDE GLYKERINGSSLUTPRODUKTER (age)
DK19210193.9T DK3677598T3 (da) 2016-02-19 2017-02-16 Fremgangsmåde og sammensætning til behandling af cancer, drab på metastatiske cancerceller og forebyggelse af cancermetastaser under anvendelse af antistof mod avancerede glykeringsslutprodukter (age)

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19210193.9T DK3677598T3 (da) 2016-02-19 2017-02-16 Fremgangsmåde og sammensætning til behandling af cancer, drab på metastatiske cancerceller og forebyggelse af cancermetastaser under anvendelse af antistof mod avancerede glykeringsslutprodukter (age)

Country Status (17)

Country Link
US (1) US11833202B2 (da)
EP (3) EP3677598B1 (da)
JP (2) JP6722293B2 (da)
KR (2) KR102536017B1 (da)
CN (1) CN109071675A (da)
AU (1) AU2017219749B2 (da)
CA (1) CA3021150C (da)
DK (2) DK3337829T3 (da)
ES (2) ES2770787T3 (da)
HK (1) HK1256931A1 (da)
HU (2) HUE047922T2 (da)
IL (2) IL261006B (da)
MX (2) MX2018009988A (da)
PL (1) PL3337829T3 (da)
PT (1) PT3337829T (da)
RU (1) RU2728964C2 (da)
WO (1) WO2017143073A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
ES2908203T3 (es) 2014-09-19 2022-04-28 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
ES2770787T3 (es) 2016-02-19 2020-07-03 Siwa Corp Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE)
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
JP2020521117A (ja) 2017-05-04 2020-07-16 シワ コーポレーション 診断用終末糖化産物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020023532A1 (en) * 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
WO2020041625A1 (en) 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
EP4143238A1 (en) 2020-05-01 2023-03-08 Siwa Corporation Methods of treating infections
US20240000930A1 (en) 2020-12-09 2024-01-04 Siwa Corporation Methods and compositions for treating kidney diseases
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases

Family Cites Families (165)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US5811075A (en) 1984-03-19 1998-09-22 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
US4900747A (en) 1984-03-19 1990-02-13 The Rockefeller University Method and agents for removing advanced glycosylation endproducts
JP2644767B2 (ja) 1986-09-12 1997-08-25 ザ ロックフェラー ユニバーシティ 後生的なグリコシル化最終産物を除去する為の方法及び薬剤
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4917951A (en) 1987-07-28 1990-04-17 Micro-Pak, Inc. Lipid vesicles formed of surfactants and steroids
US4965288A (en) 1988-02-25 1990-10-23 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US20080063603A1 (en) 1990-04-02 2008-03-13 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
US20040208826A1 (en) 1990-04-02 2004-10-21 Bracco International B.V. Ultrasound contrast agents and methods of making and using them
IN172208B (da) 1990-04-02 1993-05-01 Sint Sa
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5624804A (en) 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
DE69214672T2 (de) 1991-12-20 1997-04-03 Technomed Medical Systems Schallwellen aussendende,thermische effekte und kavitationseffekte erzeugende vorrichtung fur die ultraschalltherapie
WO1994000592A1 (en) 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
US5620479A (en) 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5518720A (en) 1992-12-30 1996-05-21 Exocell, Inc. Treatment of complications of diabetes with substances reactive with the fructosyl-lysine structure in glycated albumin
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
US5744300A (en) 1993-03-24 1998-04-28 Geron Corporation Methods and reagents for the identification and regulation of senescence-related genes
JPH09500102A (ja) 1993-04-28 1997-01-07 ウォーセスター ファウンデーション フォー エクスペリメンタル バイオロジー 細胞指向性溶解孔形成剤
JPH09511492A (ja) 1994-02-03 1997-11-18 ザ ピコワー インスティテュート フォア メディカル リサーチ アミロイドーシスの前進性グリコシル化終末産物仲介モジュレーション用組成物及び方法
US6410598B1 (en) 1994-02-03 2002-06-25 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5744318A (en) 1994-12-30 1998-04-28 Alteon Inc. Monoclonal antibody for the detection of advanced glycosylation endproducts in biological samples
DE69531311T2 (de) 1994-12-30 2004-04-22 Alteon Inc. Monoklonale antikörper spezifisch für endprodukte der fortgeschrittenen glycosylation in biologischen proben
US6176842B1 (en) 1995-03-08 2001-01-23 Ekos Corporation Ultrasound assembly for use with light activated drugs
WO1997007803A1 (en) 1995-08-25 1997-03-06 Case Western Reserve University Process for detecting pentosidine and for assessing the biological age of a biological sample
US5620409A (en) 1995-09-15 1997-04-15 The Research Foundation Of State University Of New York Method for inhibiting clot formation
JP3579549B2 (ja) 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US5664570A (en) 1996-02-20 1997-09-09 Svc Apparatus for applying high-intensity ultrasonic waves to a target volume within a human or animal body
US5908925A (en) 1996-06-27 1999-06-01 Exocell, Inc. Genetically engineered immunoglobulins with specificity for glycated albumin
US5984882A (en) 1996-08-19 1999-11-16 Angiosonics Inc. Methods for prevention and treatment of cancer and other proliferative diseases with ultrasonic energy
US6261537B1 (en) 1996-10-28 2001-07-17 Nycomed Imaging As Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US6245318B1 (en) 1997-05-27 2001-06-12 Mallinckrodt Inc. Selectively binding ultrasound contrast agents
US7101838B2 (en) 1997-08-05 2006-09-05 The Trustees Of Columbia University In The City Of New York Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts
CN1270637A (zh) 1997-08-08 2000-10-18 华盛顿大学 新的衰老因子基因p23的分离
US6380165B1 (en) 1997-09-19 2002-04-30 The Picower Institute For Medical Research Immunological advanced glycation endproduct crosslink
US6896659B2 (en) 1998-02-06 2005-05-24 Point Biomedical Corporation Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
JP4016304B2 (ja) 1998-02-26 2007-12-05 日本油脂株式会社 モノクローナル抗体、ハイブリッド細胞、およびモノクローナル抗体の製造方法
JP2002517224A (ja) 1998-06-09 2002-06-18 アルテオン インコーポレーテッド 生体サンプル内におけるグアニジノ基由来進行グリコシル化最終生成物に特異的なモノクローナル抗体
US6753150B2 (en) * 1998-10-05 2004-06-22 The Trustees Of Columbia University In The City Of New York Method for determining whether a compound is capable of inhibiting the interaction of a peptide with rage
EP1121454B1 (en) 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US6309355B1 (en) 1998-12-22 2001-10-30 The Regents Of The University Of Michigan Method and assembly for performing ultrasound surgery using cavitation
JP2002538170A (ja) 1999-03-02 2002-11-12 セントコール， インコーポレイテッド 喘息の治療における抗−ＴＮＦα抗体
US6067859A (en) 1999-03-04 2000-05-30 The Board Of Regents, The University Of Texas System Optical stretcher
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
EP1307219A4 (en) 1999-08-13 2005-04-06 Univ Columbia PROCESS FOR INHIBITING THE BINDING OF BETA FOLDED FIBRILLES TO RAGE (ADVANCED GLYCATION ENDPRODUCT RECEPTOR)
WO2001018060A1 (fr) 1999-09-08 2001-03-15 Toray Industries, Inc. Materiaux de circulation extracorporelle, adsorbants de facteurs de complication diabetique, reservoirs servant a eliminer des facteurs de complication diabetique et procede d'elimination de facteurs de complication diabetique
US6853864B2 (en) 2000-02-02 2005-02-08 Catholic University Of America, The Use of electromagnetic fields in cancer and other therapies
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
EP1283728A2 (en) 2000-05-23 2003-02-19 Amersham Health AS Contrast agents
NO312338B1 (no) 2000-08-25 2002-04-29 Gunnar Myhr Anordning for selektiv celle- eller virusödeleggelse hos en levende organisme
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CN2445326Y (zh) 2000-10-09 2001-08-29 刘永详 测定被糖化蛋白的免疫分析装置
US6676963B1 (en) 2000-10-27 2004-01-13 Barnes-Jewish Hospital Ligand-targeted emulsions carrying bioactive agents
US7481781B2 (en) 2000-11-17 2009-01-27 Gendel Limited Ultrasound therapy
US6821274B2 (en) 2001-03-07 2004-11-23 Gendel Ltd. Ultrasound therapy for selective cell ablation
EP1362223B1 (en) 2001-01-03 2008-05-21 Ultrashape Inc. Non-invasive ultrasonic body contouring
US7347855B2 (en) 2001-10-29 2008-03-25 Ultrashape Ltd. Non-invasive ultrasonic body contouring
ATE283481T1 (de) 2001-03-22 2004-12-15 Hoffmann La Roche Verfahren zum auffinden von reagenzien und festphasenkomponenten in spezifischen bindungsassays, frei von fortgeschrittenen glykosylierungsendprodukten
WO2003008446A1 (fr) 2001-07-19 2003-01-30 Mitsubishi Pharma Corporation Polypeptides se rapportant au transfert de signaux de recepteur de produits terminaux a glycation avancee
JP4012722B2 (ja) 2001-11-22 2007-11-21 株式会社トランスジェニック カルボキシメチル化ペプチドに対する抗体
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7541150B2 (en) 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
CA2492964C (en) 2002-07-24 2012-07-17 Qlt Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
EP1575513A4 (en) 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
US20070128117A1 (en) 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
EP1597280B2 (en) 2003-02-26 2016-08-24 Institute for Research in Biomedicine Monoclonal antibody production by ebv transformation of b cells
US7700307B2 (en) 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
US20060122543A1 (en) 2003-07-31 2006-06-08 Woodwelding Ag Method for promoting tissue regeneration on wound surfaces as device and treatment instrument or implant for carrying out method
US7358226B2 (en) 2003-08-27 2008-04-15 The Regents Of The University Of California Ultrasonic concentration of drug delivery capsules
EP2213310A1 (en) 2004-01-20 2010-08-04 Sunnybrook and Women's College Health Sciences Centre High frequency ultrasound imaging using contrast agents
JP2007523908A (ja) 2004-02-17 2007-08-23 ダイナミス セラピューティクス インコーポレイテッド フルクトサミン３キナーゼ並びにコラーゲン及びエラスチンの形成
EP1771565B1 (en) * 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
AP2007003869A0 (en) 2004-08-03 2007-02-28 Transtech Pharma Inc Rage fusion proteins and methods of use
GB0422525D0 (en) 2004-10-11 2004-11-10 Luebcke Peter Dermatological compositions and methods
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
US7846100B2 (en) 2005-03-03 2010-12-07 Bracco International Bv Medical imaging system based on a targeted contrast agent
JP2006249015A (ja) 2005-03-11 2006-09-21 Mochida Pharmaceut Co Ltd 細胞老化抑制剤
KR20070094950A (ko) 2005-04-05 2007-09-27 가부시끼가이샤 제이엠에스 3,4-ｄｇｅ에서 유래하는 ａｇｅ에 특이적으로 반응하는항체
JP2006288864A (ja) 2005-04-13 2006-10-26 Padoru:Kk 外科手術用の骨固定具
US20070225242A1 (en) 2005-06-21 2007-09-27 The Board Of Trustees Of The Leland Stanford Junior University Method and composition for treating and preventing tumor metastasis in vivo
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007027584A2 (en) 2005-08-30 2007-03-08 University Of Virginia Patent Foundation Deposit contrast agents and related methods thereof
US20070065415A1 (en) 2005-09-16 2007-03-22 Kleinsek Donald A Compositions and methods for the augmentation and repair of defects in tissue
US20070083120A1 (en) 2005-09-22 2007-04-12 Cain Charles A Pulsed cavitational ultrasound therapy
US20070078290A1 (en) 2005-09-30 2007-04-05 Esenaliev Rinat O Ultrasound-based treatment methods for therapeutic treatment of skin and subcutaneous tissues
US7766833B2 (en) 2005-11-23 2010-08-03 General Electric Company Ablation array having independently activated ablation elements
JP4779115B2 (ja) 2005-12-16 2011-09-28 国立大学法人東北大学 早期肺癌の術後予後検査方法
US20100226932A1 (en) 2006-02-22 2010-09-09 Novavax, Inc. Adjuvant and Vaccine Compositions
LT2676967T (lt) 2006-02-28 2019-09-10 Biogen Ma Inc. Uždegiminių ir autoimuninių ligų gydymo būdai su natalizumabu
US9056905B2 (en) 2007-05-21 2015-06-16 Alderbio Holdings Llc Antibodies to TNF-α and use thereof
US20100249038A1 (en) * 2007-06-12 2010-09-30 Board Of Regents, University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)
KR101361355B1 (ko) 2007-06-14 2014-02-12 갈락티카 파마슈티칼스, 인크. Ｒａｇｅ 융합 단백질
JP2007277263A (ja) 2007-07-13 2007-10-25 Transgenic Inc カルボキシメチル化タンパク質に対する抗体
US20120156134A1 (en) 2007-12-20 2012-06-21 Shayne Squires Compositions and methods for detecting or eliminating senescent cells to diagnose or treat disease
US7751057B2 (en) 2008-01-18 2010-07-06 The Board Of Trustees Of The University Of Illinois Magnetomotive optical coherence tomography
DE102008009461A1 (de) 2008-02-15 2009-08-20 Beiersdorf Ag Verfahren zur Reduzierung der Zeichen der Hautalterung
CA2723219A1 (en) 2008-05-09 2009-11-12 Abbott Gmbh & Co. Kg Antibodies to receptor of advanced glycation end products (rage) and uses thereof
ES2616728T3 (es) 2008-05-23 2017-06-14 Siwa Corporation Procedimientos y composiciones para facilitar la regeneración
JP5229473B2 (ja) 2008-06-04 2013-07-03 財団法人ヒューマンサイエンス振興財団 超音波医療装置
WO2010005531A2 (en) 2008-06-30 2010-01-14 The Johns Hopkins University Methods for the detection of advanced glycation endproducts and markers for disease
WO2010095461A1 (ja) 2009-02-20 2010-08-26 国立大学法人東京大学 新規モノクローナル抗体、並びにその使用
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
WO2011035104A1 (en) 2009-09-17 2011-03-24 Sanuwave, Inc. Methods and devices for cleaning and sterilization with shock waves
US20110070227A1 (en) 2009-09-18 2011-03-24 Anna-Marie Novotney-Barry Treatment of Autoimmune and Inflammatory Diseases
WO2011053322A1 (en) 2009-10-30 2011-05-05 University Of Arkansas For Medical Science Use of autologous effector cells and antibodies for treatment of multiple myeloma
WO2011101039A1 (en) 2010-02-22 2011-08-25 Universite Pierre Et Marie Curie (Paris 6) Apparatus for the treatment of brain affections and method implementing thereof
KR101351181B1 (ko) 2010-05-11 2014-01-14 가천대학교 산학협력단 단핵식세포계 세포 내에서 ａｇｅ-알부민의 합성 저해 또는 분비 저해에 의한 세포사 유도 저해 방법
ES2725852T3 (es) 2010-09-27 2019-09-27 Siwa Corp Eliminación selectiva de células modificadas por AGE para el tratamiento de la aterosclerosis
US8721571B2 (en) 2010-11-22 2014-05-13 Siwa Corporation Selective removal of cells having accumulated agents
WO2012135616A1 (en) 2011-03-31 2012-10-04 Siwa Corporation Vaccination against advanced glycation end-products
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
US9452302B2 (en) 2011-07-10 2016-09-27 Guided Therapy Systems, Llc Systems and methods for accelerating healing of implanted material and/or native tissue
US8954155B2 (en) 2011-09-19 2015-02-10 Biotalk Technologies Inc Apparatus and method for rejuvenating skin
US9422365B2 (en) 2011-09-23 2016-08-23 Julius-Maximilians-Universität Würzburg Peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
KR101939401B1 (ko) 2011-11-10 2019-01-16 가천대학교 산학협력단 단핵식세포계 세포의 ａｇｅ-알부민 합성 또는 분비 저해제를 유효성분으로 포함하는 허혈성 심장질환 예방 또는 치료용 조성물
CA2859385A1 (en) 2011-12-13 2013-06-20 Buck Institute For Research On Aging Methods for improving medical therapies
US9493566B2 (en) 2012-02-17 2016-11-15 Seattle Genetics, Inc. Antibodies to integrin AVB6 and use of same to treat cancer
TWI557112B (zh) 2012-03-05 2016-11-11 百靈佳殷格翰國際股份有限公司 β－分泌酶抑制劑
US20130288980A1 (en) 2012-04-02 2013-10-31 Buck Institute For Research On Aging Targeting senescent and cancer cells for selective killing by interference with foxo4
US10379026B2 (en) 2012-08-29 2019-08-13 Inguran, Llc Cell processing using magnetic particles
KR101520336B1 (ko) 2012-11-30 2015-05-14 전남대학교산학협력단 패혈증 비브리오균의 편모 구성성분인 플라젤린과 병원체의 항원 단백을 융합시킨 재조합 단백을 포함하는 노화 예방, 개선 또는 치료용 조성물
WO2014089124A1 (en) 2012-12-03 2014-06-12 Cenexys, Inc. Immunogenic compositions for inducing an immune response for elimination of senescent cells
EP2742935A1 (en) 2012-12-14 2014-06-18 Tissue Med Biosciences Forschungs- und Entwicklungsgesellschaft mbH SERF2 for the treatment of atrophy and for increasing cell growth
US20160017021A1 (en) 2013-03-06 2016-01-21 Protalix Ltd. TNF alpha INHIBITOR POLYPEPTIDES, POLYNUCLEOTIDES ENCODING SAME, CELLS EXPRESSING SAME AND METHODS OF PRODUCING SAME
US20140257262A1 (en) 2013-03-11 2014-09-11 Alexandre Carpentier Interstitial ultrasonic disposable applicator and method for tissue thermal conformal volume ablation and monitoring the same
RS60280B1 (sr) 2013-03-12 2020-06-30 Molecular Templates Inc Citotoksični proteini koji sadrže ciljane vezujuće regione za ćelije i regioni shiga toksina a podjedinice za selektivno ubijanje određenih vrsta ćelija
CN105705522B (zh) 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
PE20161394A1 (es) 2013-12-16 2017-01-06 Genentech Inc Compuestos peptidomimeticos y sus conjugados de anticuerpo-farmaco
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3094350B1 (en) 2014-01-15 2020-03-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cartilage targeting agents and their use
EP3096824A1 (en) 2014-01-24 2016-11-30 Cole Research&Design, Inc. Oral suction device
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
SG10201805670QA (en) 2014-01-28 2018-08-30 Buck Inst Res Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10238742B2 (en) 2014-06-25 2019-03-26 Yale University Cell penetrating nucleolytic antibody based cancer therapy
ES2908203T3 (es) 2014-09-19 2022-04-28 Siwa Corp Anticuerpos anti-age para el tratamiento de inflamación y trastornos autoinmunes
EP3207062A1 (en) * 2014-10-16 2017-08-23 The Broad Institute Inc. Compositions and methods for identifying and treating cachexia or pre-cachexia
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
KR20180056689A (ko) * 2015-10-13 2018-05-29 시와 코퍼레이션 항-age 항체 및 이의 사용 방법
US10889634B2 (en) 2015-10-13 2021-01-12 Siwa Corporation Anti-age antibodies and methods of use thereof
ES2770787T3 (es) 2016-02-19 2020-07-03 Siwa Corp Método y composición para tratar el cáncer, destruir las células cancerosas metastásicas y evitar la metástasis del cáncer usando anticuerpo para productos finales de glicación avanzada (AGE)
WO2018191718A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
US10981021B2 (en) 2016-03-11 2021-04-20 Carthera Method for transiently disrupting a region of the blood-brain barrier of a human
WO2017181116A1 (en) 2016-04-15 2017-10-19 Siwa Corporation Anti-age antibodies for treating neurodegenerative disorders
US10172684B2 (en) 2016-04-29 2019-01-08 Ethicon Llc Lifecycle monitoring features for surgical instrument
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
RU2617313C1 (ru) 2016-07-18 2017-04-24 Государственное автономное учреждение здравоохранения Свердловской области "Центр специализированных видов медицинской помощи "Институт медицинских клеточных технологий" Способ определения биологического возраста у мужчин
US10858449B1 (en) 2017-01-06 2020-12-08 Siwa Corporation Methods and compositions for treating osteoarthritis
US10995151B1 (en) 2017-01-06 2021-05-04 Siwa Corporation Methods and compositions for treating disease-related cachexia
US10961321B1 (en) 2017-01-06 2021-03-30 Siwa Corporation Methods and compositions for treating pain associated with inflammation
US10925937B1 (en) 2017-01-06 2021-02-23 Siwa Corporation Vaccines for use in treating juvenile disorders associated with inflammation
JP2020521117A (ja) 2017-05-04 2020-07-16 シワ コーポレーション 診断用終末糖化産物抗体
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
WO2020023532A1 (en) 2018-07-23 2020-01-30 Siwa Corporation Methods and compositions for treating chronic effects of radiation and chemical exposure
JP2021533827A (ja) 2018-08-14 2021-12-09 イメル バイオセラピューティクス，インク． ミトコンドリア疾患又は障害及びヘテロプラスミーを治療するための方法及び組成物
WO2020041625A1 (en) 2018-08-23 2020-02-27 Siwa Corporation Anti carboxymethyl lysine antibodies and ultrasound for removing age-modified cells
EP4143238A1 (en) 2020-05-01 2023-03-08 Siwa Corporation Methods of treating infections
WO2021247397A2 (en) 2020-06-04 2021-12-09 Siwa Corporation Methods and compositions for enhancing the immune system
WO2022093195A1 (en) 2020-10-27 2022-05-05 Siwa Corporation Methods and compositions for treating osteoarthritis using anti-age antibodies or age antigens
WO2023023654A1 (en) 2021-08-20 2023-02-23 Siwa Corporation Methods and compositions for treating fibrotic diseases
WO2023177390A1 (en) 2022-03-14 2023-09-21 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody for treating pancreatic cancer

Also Published As

Publication number Publication date
AU2017219749B2 (en) 2022-01-06
HUE047922T2 (hu) 2020-05-28
JP6811887B2 (ja) 2021-01-13
IL261006A (en) 2018-10-31
EP3337829A1 (en) 2018-06-27
PL3337829T3 (pl) 2020-05-18
RU2018132998A3 (da) 2020-05-29
DK3677598T3 (da) 2022-05-30
PT3337829T (pt) 2020-02-10
EP3337829B1 (en) 2020-01-08
MX2018009988A (es) 2018-12-17
WO2017143073A1 (en) 2017-08-24
US20190031781A1 (en) 2019-01-31
JP2019511469A (ja) 2019-04-25
JP6722293B2 (ja) 2020-07-15
EP3677598A1 (en) 2020-07-08
IL261006B (en) 2021-06-30
ES2912064T3 (es) 2022-05-24
KR20180110090A (ko) 2018-10-08
AU2017219749A1 (en) 2018-08-23
RU2018132998A (ru) 2020-03-19
KR20230074837A (ko) 2023-05-31
HUE058854T2 (hu) 2022-09-28
IL283726A (en) 2021-07-29
ES2770787T3 (es) 2020-07-03
CA3021150A1 (en) 2017-08-24
CN109071675A (zh) 2018-12-21
CA3021150C (en) 2023-02-07
KR102536017B1 (ko) 2023-05-24
RU2728964C2 (ru) 2020-08-03
MX2022014630A (es) 2023-02-23
HK1256931A1 (zh) 2019-10-04
EP3677598B1 (en) 2022-04-06
EP4067386A1 (en) 2022-10-05
JP2020158531A (ja) 2020-10-01
US11833202B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
DK3337829T3 (da) FREMGANGSMÅDE OG SAMMENSÆTNING TIL BEHANDLING AF CANCER, DRAB AF METASTATISKE CANCERCELLER OG FOREBYGGELSE AF CANCERMETASTASE VED HJÆLP AF ANTISTOFFER MOD AVANCEREDE GLYKERINGSSLUTPRODUKTER (age)
DK3458478T3 (da) Anti-pd-1- og anti-lag3-antistoffer til cancerbehandling
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
DK3153169T3 (da) Fremgangsmåde til behandling af tumor, farmaceutisk sammensætning og medicinæskesæt
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3676297T3 (da) Forbindelser, sammensætninger og fremgangsmåder
DK3378859T3 (da) Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3204386T3 (da) Substituerede aminopurinforbindelser, sammensætninger deraf og fremgangsmåder til behandling dermed
DK3134130T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3381469T3 (da) Anti-erbb2 antistoflægemiddelskonjugat og sammensætning deraf, fremgangsmåde til fremstilling deraf og anvendelse deraf
DK3200815T3 (da) Fremgangsmåder og sammensætninger til behandling af cancer
DK3348276T3 (da) Cancerbehandlingssammensætning, hvor af anti-CD26-antistof og et andet anticancermiddel er kombineret
BR112017024253A2 (pt) métodos de tratamento de inflamação ou dor neuropática.
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3110446T3 (da) Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3750893T3 (da) Dioxazolinforbindelse, fremgangsmåde til fremstilling deraf og anvendelser deraf
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3471722T3 (da) Forbindelser, sammensætninger og fremgangsmåder til forebyggelse og/eller behandling af cancer
DK3478284T3 (da) Forbindelser og sammensætninger til behandling af cancer
DK3242869T3 (da) Sammensætninger og fremgangsmåder til behanding af inflammation og smerte
EA201691896A1 (ru) Соединения и способы их применения
EP3294301A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH
DK3290051T3 (da) Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
DK3630112T3 (da) Kombination af regorafenib og nivolumab til behandling af cancer